Premium
Serum β 2 ‐microglobulin at remission and relapse in patients with multiple myeloma
Author(s) -
BRENNING G.,
WIBELL L.,
BERGSTRÖM R.
Publication year - 1985
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1985.tb00177.x
Subject(s) - beta 2 microglobulin , multiple myeloma , medicine , oncology
. Serum β 2 ‐microglobulin (S‐β 2 m) was determined before treatment in fifty patients with multiple myeloma (MM), twenty‐two of which had pure Bence Jones (BJ) myeloma. S‐β 2 m was related to clinical stage before, but not after, a correction of S‐β 2 m values for co‐existent raised S‐creatinine values (> 106 μmol 1 ‐1 )‐ However, S‐β 2 m as well as corrected β 2 m was a parameter of prognostic value. The median expected survival time was 14 months at S‐β 2 m values > 8·0 mg 1 ‐1 and 56 months at values<3·5 mg 1 ‐1 . A response to treatment was associated with a decrease of S‐β 2 m and a stationary course with unchanged values, whereas a relapse or progressive disease was connected with an increase. In β 2 m producers', i.e. patients with a clear initial high S‐β 2 m, serial determinations are of value for monitoring patients with MM. In particular, this is the case in BJ myelomas, as they lack a quantifiable serum M‐component. With respect to β 2 m no difference was found between BJ and other patients with MM.